About Vedanta Biosciences
Vedanta Biosciences is a company based in Cambridge (United States) founded in 2010. It operates as a HealthTech. Vedanta Biosciences has raised $350.49 million across 13 funding rounds from investors including Pfizer, PureTech Health and Korea Investment Holdings. The company has 71 employees as of December 31, 2022. Vedanta Biosciences offers products and services including VE303, VE707, and VE202. Vedanta Biosciences operates in a competitive market with competitors including Biogen, UCB, Grifols, Kymeratx and Kriya Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 71 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Vedanta Biosciences, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$350.49 M (USD)
in 13 rounds
-
Latest Funding Round
-
Investors
Pfizer
& 37 more
-
Employee Count
71
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Vedanta Biosciences
Vedanta Biosciences offers a comprehensive portfolio of products and services, including VE303, VE707, and VE202. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Developed for treating recurrent Clostridium difficile infection effectively.
Designed to address gastrointestinal infections and inflammation issues.
Formulated for managing inflammatory bowel disease in patients.
Unlock access to complete
Unlock access to complete
Funding Insights of Vedanta Biosciences
Vedanta Biosciences has successfully raised a total of $350.49M across 13 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 13
- Last Round Last Round
-
First Round
First Round
(06 Jun 2016)
- Investors Count 38
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2024 | Amount | Series E - Vedanta Biosciences | Valuation | Colorcon | |
| Mar, 2023 | Amount | Series E - Vedanta Biosciences | Valuation | AXA Investment Managers , AMR Action Fund | |
| Jul, 2021 | Amount | Series D - Vedanta Biosciences | Valuation | Magnetar |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Vedanta Biosciences
Vedanta Biosciences has secured backing from 38 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, PureTech Health and Korea Investment Holdings. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified alternative assets are managed through investment strategies.
|
Founded Year | Domain | Location | |
|
Investments are made in antimicrobial resistance treatment development.
|
Founded Year | Domain | Location | |
|
Flexible, long-term financing solutions are provided to healthcare companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Vedanta Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Vedanta Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Vedanta Biosciences Comparisons
Competitors of Vedanta Biosciences
Vedanta Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, UCB, Grifols, Kymeratx and Kriya Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for immunological and neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-derived therapies are developed to treat multiple diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Vedanta Biosciences
Frequently Asked Questions about Vedanta Biosciences
When was Vedanta Biosciences founded?
Vedanta Biosciences was founded in 2010 and raised its 1st funding round 6 years after it was founded.
Where is Vedanta Biosciences located?
Vedanta Biosciences is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Vedanta Biosciences?
Bernat Olle is the current CEO of Vedanta Biosciences.
Is Vedanta Biosciences a funded company?
Vedanta Biosciences is a funded company, having raised a total of $350.49M across 13 funding rounds to date. The company's 1st funding round was a Series D of $68M, raised on Jun 06, 2016.
How many employees does Vedanta Biosciences have?
As of Dec 31, 2022, the latest employee count at Vedanta Biosciences is 71.
What does Vedanta Biosciences do?
Vedanta Biosciences, Inc. is engaged in the development of first-in-class Live Biotherapeutic Products (LBP) using defined bacterial consortia. The company targets serious gastrointestinal diseases, including Clostridium difficile infection and inflammatory bowel disease. Solutions are designed to address gut dysbiosis, a key driver of inflammatory and infectious GI conditions, by stimulating immune responses. Clinical trials such as RESTORATiVE303 and COLLECTiVE202 are conducted to evaluate the efficacy and safety of drug candidates. The pipeline includes VE303, VE707, and VE202, aimed at advancing treatments in gastrointestinal inflammation and infection sectors.
Who are the top competitors of Vedanta Biosciences?
Vedanta Biosciences's top competitors include BioNTech, Generate Biomedicines and Kymeratx.
What products or services does Vedanta Biosciences offer?
Vedanta Biosciences offers VE303, VE707, and VE202.
Who are Vedanta Biosciences's investors?
Vedanta Biosciences has 38 investors. Key investors include Pfizer, PureTech Health, Korea Investment Holdings, Gates Foundation, and Shinhan Financial Group.